The catabolic effect of TNFa on bovine nucleus pulposus intervertebral disc cells and the restraining role of glucosamine sulfate in the TNFa-mediated up-regulation of MMP-3

Journal of Orthopaedic Research

Volumn 32, Issue 12, 2014, Pages 1701-1707

  Mavrogonatou, Eleni ^a   Angelopoulou, Maria T ^a   Kletsas, Dimitris ^a  

^a INSTITUTE OF NANOSCIENCE AND NANOTECHNOLOGY   (Greece)

Author keywords

Glucosamine sulfate; Inflammatory response; Intervertebral disc; MMP 3; TNF

Indexed keywords

4 (4 FLUOROPHENYL) 2 (4 METHYLSULFINYLPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; GLUCOSAMINE SULFATE; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE P38; REACTIVE OXYGEN METABOLITE; STRESS ACTIVATED PROTEIN KINASE; STROMELYSIN; TUMOR NECROSIS FACTOR ALPHA; ANTIINFLAMMATORY AGENT; GLUCOSAMINE;

ANIMAL CELL; ARTICLE; CATABOLISM; CATTLE; CELL PROLIFERATION; CELL VIABILITY; CONTROLLED STUDY; CYTOTOXICITY; ENZYME ACTIVATION; ENZYME PHOSPHORYLATION; HUMAN; HUMAN CELL; MEDIATOR; NONHUMAN; NUCLEUS PULPOSUS; UPREGULATION; ANIMAL; BOVINAE; CELL CULTURE; CELL SURVIVAL; CYTOLOGY; DRUG EFFECTS; GENETICS; INTERVERTEBRAL DISK; METABOLISM; PHYSIOLOGY; SIGNAL TRANSDUCTION;

ANIMALS; ANTI-INFLAMMATORY AGENTS; CATTLE; CELL SURVIVAL; CELLS, CULTURED; GLUCOSAMINE; INTERVERTEBRAL DISC; MAP KINASE SIGNALING SYSTEM; MATRIX METALLOPROTEINASE 3; P38 MITOGEN-ACTIVATED PROTEIN KINASES; REACTIVE OXYGEN SPECIES; TUMOR NECROSIS FACTOR-ALPHA; UP-REGULATION;

EID: 84911442360     PISSN: 07360266     EISSN: 1554527X     Source Type: Journal    
DOI: 10.1002/jor.22725     Document Type: Article

References (45)

1. Freburger JK, Holmes GM, Agans RP, et al. 2009. The rising prevalence of chronic low back pain. Arch Intern Med 169: 251-258.
2. Katz JN. 2006. Lumbar disc disorders and low-back pain: socioeconomic factors and consequences. J Bone Joint Surg Am 88:21-24.
3. Maniadakis N, Gray A. 2000. The economic burden of back pain in the UK. Pain 84:95-103.
4. Strong JA, Xie W, Bataille FJ, et al. 2013. Preclinical studies of low back pain. Mol Pain 9:17.
5. Miller SM. 2012. Low back pain: pharmacologic management. Prim Care 39:499-510.
6. Luoma K, Riihimaki H, Luukkonen R, et al. 2000. Low back pain in relation to lumbar disc degeneration. Spine (Phila Pa 1976) 25:487-492.
7. Urban JP, Roberts S. 2003. Degeneration of the interverte-bral disc. Arthritis Res Ther 5:120-130.
8. Roberts S, Evans H, Trivedi J, et al. 2006. Histology and pathology of the human intervertebral disc. J Bone Joint Surg Am 88:10-14.
9. Le Maitre CL, Freemont AJ, Hoyland JA. 2004. Localization of degradative enzymes and their inhibitors in the degenerate human intervertebral disc. J Pathol 204:47-54.
10. Le Maitre CL, Freemont AJ, Hoyland JA. 2006. Human disc degeneration is associated with increased MMP 7 expression. Biotech Histochem 81:125-131.
11. Le Maitre CL, Pockert A, Buttle DJ, et al. 2007. Matrix synthesis and degradation in human intervertebral disc degeneration. Biochem Soc Trans 35:652-655.
12. Le Maitre CL, Hoyland JA, Freemont AJ. 2007. Catabolic cytokine expression in degenerate and herniated human intervertebral discs: IL-1beta and TNFalpha expression profile. Arthritis Res Ther 9:R77.
13. Millward-Sadler SJ, Costello PW, Freemont AJ, et al. 2009. Regulation of catabolic gene expression in normal and degenerate human intervertebral disc cells: implications for the pathogenesis of intervertebral disc degeneration. Arthritis Res Ther 11:R65.
14. Tian Y, Yuan W, Fujita N, et al. 2013. Inflammatory cytokines associated with degenerative disc disease control aggrecanase-1 (ADAMTS-4) expression in nucleus pulposus cells through MAPK and NF-kappaB. Am J Pathol 182: 2310-2321.
15. Bachmeier BE, Nerlich AG, Weiler C, et al. 2007. Analysis of tissue distribution of TNF-alpha, TNF-alpha-receptors, and the activating TNF-alpha-converting enzyme suggests activation of the TNF-alpha system in the aging intervertebral disc. Ann N Y Acad Sci 1096:44-54.
16. Weiler C, Nerlich AG, Bachmeier BE, et al. 2005. Expression and distribution of tumor necrosis factor alpha in human lumbar intervertebral discs: a study in surgical specimen and autopsy controls. Spine (Phila Pa 1976) 30:44-53; discussion 54.
17. Seguin CA, Pilliar RM, Roughley PJ, et al. 2005. Tumor necrosis factor-alpha modulates matrix production and ca-tabolism in nucleus pulposus tissue. Spine (Phila Pa 1976) 30:1940-1948.
18. Seguin CA, Pilliar RM, Madri JA, et al. 2008. TNF-alpha induces MMP2 gelatinase activity and MT1-MMP expression in an in vitro model of nucleus pulposus tissue degeneration. Spine (Phila Pa 1976) 33:356-365.
19. Dodge GR, Jimenez SA. 2003. Glucosamine sulfate modulates the levels of aggrecan and matrix metalloproteinase-3 synthesized by cultured human osteoarthritis articular chondrocytes. Osteoarthritis Cartilage 11:424-432.
20. Mavrogonatou E, Kletsas D. 2013. The effect of glucosamine sulfate on the proliferative potential and glycosaminoglycan synthesis of nucleus pulposus intervertebral disc cells. Spine (Phila Pa 1976) 38:308-314.
21. Burdett N, McNeil JD. 2012. Difficulties with assessing the benefit of glucosamine sulphate as a treatment for osteoar-thritis. Int J Evid Based Healthc 10:222-226.
22. Walsh AJ, O'Neill CW, Lotz JC. 2007. Glucosamine HCl alters production of inflammatory mediators by rat interver-tebral disc cells in vitro. Spine J 7:601-608.
23. Burke JG, Watson RW, McCormack D, et al. 2002. Interver-tebral discs which cause low back pain secrete high levels of proinflammatory mediators. J Bone Joint Surg Br 84:196-201.
24. Alini M, Eisenstein SM, Ito K, et al. 2008. Are animal models useful for studying human disc disorders/degeneration? Eur Spine J 17:2-19.
25. Mavrogonatou E, Kletsas D. 2009. High osmolality activates the G1 and G2 cell cycle checkpoints and affects the DNA integrity of nucleus pulposus intervertebral disc cells triggering an enhanced DNA repair response. DNA Repair (Amst) 8:930-943.
26. Mavrogonatou E, Kletsas D. 2010. Effect of varying osmotic conditions on the response of bovine nucleus pulposus cells to growth factors and the activation of the ERK and Akt pathways. J Orthop Res 28:1276-1282.
27. Mavrogonatou E, Kletsas D. 2012. Differential response of nucleus pulposus intervertebral disc cells to high salt, sorbitol, and urea. J Cell Physiol 227:1179-1187.
28. Mavrogonatou E, Eliades T, Eliades G, et al. 2010. The effect of triethylene glycol dimethacrylate on p53-dependent G2 arrest in human gingival fibroblasts. Biomaterials 31:8530-8538.
29. Athanasas K, Magiatis P, Fokialakis N, et al. 2004. Hyper-jovinols A and B: two new phloroglucinol derivatives from Hypericum jovis with antioxidant activity in cell cultures. J Nat Prod 67:973-977.
30. Livak KJ, Schmittgen TD. 2001. Analysis of relative gene expression data using real-time quantitative PCR and the 2 (-Delta Delta C(T)) Method. Methods 25:402-408.
31. Scotto d'Abusco A, Cicione C, Calamia V, et al. 2007. Glucosamine and its N-acetyl-phenylalanine derivative prevent TNF-alpha-induced transcriptional activation in human chondrocytes. Clin Exp Rheumatol 25: 847-852.
32. Almeida M, Han L, Ambrogini E, et al. 2011. Glucocorticoids and tumor necrosis factor alpha increase oxidative stress and suppress Wnt protein signaling in osteoblasts. J Biol Chem 286:44326-44335.
33. Wuertz K, Vo N, Kletsas D, et al. 2012. Inflammatory and catabolic signalling in intervertebral discs: the roles of NF-kappaB and MAP kinases. Eur Cell Mater 23:103-119 discussion 119-120.
34. Shikhman AR, Kuhn K, Alaaeddine N, et al. 2001. N-acetylglucosamine prevents IL-1 beta-mediated activation of human chondrocytes. J Immunol 166:5155-5160.
35. d'Abusco AS, Calamia V, Cicione C, et al. 2007. Glucosamine affects intracellular signalling through inhibition of mito-gen-activated protein kinase phosphorylation in human chondrocytes. Arthritis Res Ther 9: R104.
36. Lin YC, Liang YC, Sheu MT, et al. 2008. Chondroprotective effects of glucosamine involving the p38 MAPK and Akt signaling pathways. Rheumatol Int 28:1009-1016.
37. Lu HT, Liang YC, Sheu MT, et al. 2008. Disease-modifying effects of glucosamine HCl involving regulation of metallopro-teinases and chemokines activated by interleukin-1beta in human primary synovial fibroblasts. J Cell Biochem 104:38-50.
38. Hong H, Park YK, Choi MS, et al. 2009. Differential down-regulation of COX-2 and MMP-13 in human skin fibroblasts by glucosamine-hydrochloride. J Dermatol Sci 56:43-50.
39. Ju Y, Hua J, Sakamoto K, et al. 2008. Modulation of TNF-alpha-induced endothelial cell activation by glucosamine, a naturally occurring amino monosaccharide. Int J Mol Med 22:809-815.
40. Yomogida S, Hua J, Sakamoto K, et al. 2008. Glucosamine suppresses interleukin-8 production and ICAM-1 expression by TNF-alpha-stimulated human colonic epithelial HT-29 cells. Int J Mol Med 22:205-211.
41. Park K, Lee JH, Cho HC, et al. 2010. Down-regulation of IL-6, IL-8, TNF-alpha and IL-1beta by glucosamine in HaCaT cells, but not in the presence of TNF-alpha. Oncol Lett 1:289-292.
42. Boyle DL, Jones TL, Hammaker D, et al. 2006. Regulation of peripheral inflammation by spinal p38 MAP kinase in rats. PLoS Med 3:e338.
43. Studer RK, Aboka AM, Gilbertson LG, et al. 2007. p38 MAPK inhibition in nucleus pulposus cells: a potential target for treating intervertebral disc degeneration. Spine (Phila Pa 1976) 32:2827-2833.
44. Gouze JN, Gouze E, Popp MP, et al. 2006. Exogenous glucosamine globally protects chondrocytes from the arthri-togenic effects of IL-1beta. Arthritis Res Ther 8:R173.
45. Adebowale A, Du J, Liang Z, et al. 2002. The bioavailability and pharmacokinetics of glucosamine hydrochloride and low molecular weight chondroitin sulfate after single and multiple doses to beagle dogs. Biopharm Drug Dispos 23:217-225.